Immunotherapy for Urothelial Carcinoma: Focus on Clinical Utility of Nivolumab

Over the past decade, the emergence of immune checkpoint inhibitors has brought about significant change to the treatment landscape of bladder cancer. Nivolumab is an immune checkpoint inhibitor that has shown favorable results resulting in FDA approval for treatment of platinum-refractory locally a...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiang, Ryan S, Glover, Michael J, Khaki, Ali Raza, Srinivas, Sandy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582299/
https://www.ncbi.nlm.nih.gov/pubmed/36275184
http://dx.doi.org/10.2147/OTT.S369043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582299/
https://www.ncbi.nlm.nih.gov/pubmed/36275184
http://dx.doi.org/10.2147/OTT.S369043

Ejemplares similares